BRCA1 and cancer: PARP1 inhibitors are used for the treatment of BRCA1-deficient cancers, as inhibition of PARP1 generates more single-strand DNA damage, which results in DSBs and consequently leads to a synthetic lethality with BRCA1 deficiency.